Hudson Bay Capital Management
IMRX icon

Hudson Bay Capital Management’s Immuneering IMRX Stock Holding History

Hudson Bay Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$505K Buy
95,889
+10,916
+13% +$56K ﹤0.01% 977
2025
Q4 		$559K Sell
84,973
-17,475
-17% -$112K ﹤0.01% 854
2025
Q3 		$717K Buy
+102,448
New +$532K ﹤0.01% 889

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management's IMRX Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Immuneering (IMRX) stake by 13% in Q1 2026, buying an estimated $56K and bringing the position to 95,889 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #977.

Hudson Bay Capital Management first reported a position in IMRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $717K in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Hudson Bay Capital Management held 95,889 shares of Immuneering worth $505K as of Q1 2026.
  • Hudson Bay Capital Management bought 10,916 Immuneering shares in Q1 2026, an estimated $56K.
  • Immuneering made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #977 holding.
  • Hudson Bay Capital Management first reported a position in Immuneering in Q3 2025 and has held it in 3 quarters since.
  • Hudson Bay Capital Management's Immuneering position peaked at $717K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.